Observational study / 2005
Adjuvant zinc administration alongside chemotherapy was followed by rapid bone marrow remission in a 3-year-old girl with acute lymphocytic leukemia.
A 3-year-old girl with acute lymphocytic leukemia and low blood zinc received zinc adjuvant (3.18 mg/kg body weight/day; 18 mg at breakfast and 18 mg at supper) from the start of chemotherapy through 3 years of maintenance therapy. Bone marrow blast cells decreased from 95+% to an observed zero count in both hips within 14 days, without relapse, accompanied by normalized hemopoietic functions and no observed side effects. The authors noted identical results occurred in 13 other children whose parents chose zinc adjuvant, and they hypothesize zinc may strengthen chemotherapy and immune function.
Shows an association, not proof of cause and effect.
- Study type
- Case report and hypothesis
- Who was studied
- A 3-year-old girl (and 13 other children) with acute lymphocytic leukemia (ALL)
- What was measured
- Bone marrow blast cell count, hemopoietic function, side effects, and relapse
THE PAPER
Treatment of acute lymphocytic leukemia using zinc adjuvant with chemotherapy and radiation--a case history and hypothesis.
Eby GA. Med Hypotheses, 2005.
This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.